$NWBO

It's not silence from the company, that suppress the share price.

It is plain and simple, manipulation, spoofing and counterfitting.

Guidance and information have zero effect, before AFTER approval.

It HAS been tried, and the forces aligned against NWBO, has used it ... ... against NWBO through complaints, through fraud lawsuits, through misinterpreting the info.

Best case its like pissing your pants in december walking around Nova Scotia.

What a nice feeling and then ...

You don't want to RISK have to divert attention, money and effort ...

$NWBO

If trading of an over-the-counter (OTC) stock like NWBO (Northwest Biotherapeutics) is halted in Europe, it can significantly affect market makers who have engaged in naked short selling of the stock. Here’s how: 1Liquidity Impact: With the trading halt, the liquidity of NWBO in the European market is essentially frozen. Market makers rely on liquidity to cover their short positions, including naked shorts. Without the ability to trade, they cannot buy shares to close out these positions

$NWBO

A case AGAINST reverse split (R/S)

Once again we have the "tool" R/S mentioned, as a mean with which we can uplist to Nasdaq and get institutions to buy in.

I have earlier pleaded my case against it and will continue to do so.

1/12 An R/S is market makers, shorters and fudders wet dream to make it much easier to spoof/naked shart the share price to lower levels.

NO uplist should take place founded in R/S if any of the following has not occured.

2/12

$NWBO

I asked ChatGBT, who is SIO Capital Management?

SIO Capital Management, LLC is a global equity market neutral healthcare hedge fund headquartered in New York. Founded by Dr. Michael Castor in 2006, the firm focuses exclusively on the healthcare sector .... ... which includes areas such as biotech, pharmaceuticals, medical devices, insurance, and hospitals. This specialization allows SIO to leverage its deep industry knowledge to identify investment opportunities and mispriced stocks within the complex healthcare landscape.

$NWBO

If you are STILL unaware, @SECGov and @GaryGensler are NOT a friend of "us".

Citadel and Virtu have built up an enormous liability post on their yearly financial condition statement, named

"Securities sold, not yet purchased at fair value”.

Essentially is is a ...

https://twitter.com/garygensler/status/1633198048103759873

... way for market makers to "cover up" their cumulative short and distort scams and give it a "fair value".

Ranging from 45-65 billion dollars the last couple of years, the number is a placeholder for the destruction of companies, for layoff of employees, for preventing ....

$NWBO

The Revimmune Connection

1) Northwest Biotherapeutics have a combination patent with DCVax-L and checkpoint inhibitors and Interleukin-7

2) Linda Powers is CEO of Northwest Biotherapeutics

3) Linda Powers owns Toucan Capital

4) Linda Powers is CEO of Advent Bioservices 5) Linda Powers is Director of Revimmune SAS

6) Linda Powers is Director of Revimmune Limited

7) Linda Powers was CEO of Cognate

8) Philippe Pire is CFO of Advent Bioservices

9) Philippe Pire is listed as employee at Revimmune Limited

10) J Kelly Ganjei is CEO of AmplifyBio

$NWBO

NO. I do NOT agree on low BO numbers, no matter WTF the number of outstanding/authorized share number count is.

Now I am talking to the rational and reasonable, who likes to take in the full picture of whats going on and doesn't go into cardiac arrest ... ... , whenever one of hedge funds lapdogs tweet or post todays about insanity theme.

This is about looking at whats been done, what is going on and then use simple logic to arrive at a conclusion by sheer reasoning.

$NWBO

The IRP procedure.



Look at the bottom:

"To further streamline the IRP application process, the MHRA launched an ‘Eligibility Checker’ tool on 20 November 2023."

Let's give that news a look shall we?gov.uk/government/new… Once IRP is fully up-and-running in January, we will have created a further route for bringing new medicines to UK patients.

The launch is supported by £10m in funding from HM Treasury in March to support the development of the new recognition framework.

pharmatimes.com/news/mhra_laun…

$NWBO

This is Paul Milgrom.

In 2020, he was co-recipient of the Sveriges Riksbank Prize in Economic Sciences in Honor of Alfred Nobel “for improvements to auction theory and inventions of new auction formats.”

Safe to say. Mr. Milgrom is not stupid.

milgrom.people.stanford.edu In the red corner we have @Dougielarge and his lapdog @Tiggersdad2, who consistenly have been claiming, that spoofing has no permanent impact to share price.

Being a paid shill and rendering his services to hedges/MMs instigating the spoofing of NWBO, his incentives are clear.

$NWBO

You'll love this.

Bradley Heltemes, Vice President and Medical Director in German Münich Reassurance.

What has he to say in this French/Canadian article on Munich Re's website? Let's look at images first from the article:

Looks familiar?

$NWBO

I have researched as much as possible the last 3 years about NWBO and DCVax-L.

My optimism has only grown as we reached milestone upon milestone.

Data lock
TLD
JAMA Journal
MIA approval
PIP
Scaling and automation via Eden Flaskworks
Hiring spree at Advent Bio

https://twitter.com/woodman267/status/1687104234897170432

Then Cohen and Millstein entered the stage proving +5 years of spoofing, still ongoing, taken it on contingence with star lead lawyer Laura Posner heading it.

New presentations with DCVax-L shows method of action, attacking more than 11.000 antigens, compassionate use cases ...

16)

... but actually helping american companies, innovators, employees, patients and investors shedding light on the criminal scheme that these market makers almost succeeded at.

@jon 2)

... is ready to be approved within short by the MHRA in the UK.

It seems as if approval is seeked through project ORBIS/ILAP, thus approval could be coming in more countries.

It seems as if Ted Nesi from WPRI 12 is going to cover the breakthrough next week ...

->

$NWBO @DCarnival46

#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.

You know who got their PIP plan approved last year by the MHRA in the UK? You know who ANNOUNCED a new center of cancer excellence in Sutton in the UK two months ago, 130 miles from Sawston, focusing on DIPG?

$NWBO

Being a shareholder and being enlightened with the decade long harassment of NWBO by spoofing by several market makers - YES Cohen and Millstein HAVE taken the case on contingency as the proof of spoofing is overwhelming with +5 years of detailed trading transactions ....

https://twitter.com/Tiggersdad2/status/1639098813041491968

- and 40 hit pieces to support this by Adam Feuerstein, correlating with an army of support on stock boards by shorters, fudders and paid bashing pawns making NWBO the most debated stock for over a year on Ihub, I would say the "burning of shareholders" is a discipline incited ..

$NWBO

Let's look at news in the UK, that explicitly have pointed out the parent/child relationship of NWBO and the CDMO Advent Bioservices, situated on the same compound within the same building at Sawston, Cambridge, UK.

cambridgeindependent.co.uk/business/sawst… 1 )

"Linda Powers, CEO of Northwest Biotherapeutics (NW Bio), has paid tribute to the clinical development team at Sawston Business Park – and contractor Advent BioServices"

🇬🇧🇬🇧🇬🇧🇬🇧🇬🇧
🇬🇧 $NWBO 🇬🇧
🇬🇧🇬🇧🇬🇧🇬🇧🇬🇧

At the NYAS presentation May 5th., @StevenBremMD from UPenn was given the word by the Session Host George Zavoio, now employed by NWBO.

Dr. Stephen Brem:

"Yeah, I wanted to answer David’s question… and congratulate Paul Mulholland --> ".. the Northwest Bio team. Without being self-congratulatory… full disclosure… I’m one of the seventy authors, and we’ve been waiting for an advance like this for a long time.

"David, in addition to the external controls and the numbers, we have some unpublished data from ->

$NWBO

"We have included 5 new sites in this year’s manufacturing survey, one of which (Advent) acquired their MIA (IMP) just shortly after the publication of last year’s manufacturing report, and anticipates
gaining their MIA shortly"

cgt.ams3.cdn.digitaloceanspaces.com/Manufacturing-… "The overall picture of the dedicated GMP cell therapy
manufacturing sector is one moving in a positive direction, while the number of facilities remains static at 10, there has been a notable expansion of capacity, primarily driven by the addition of the large Advent site."

$NWBO

NWBO's been constantly the most debated stock on Investorshub.

I'm a very outspoken guy. A biotech having worked upon a cancer vaccine in 20 years, being traded at $0,68 a share, does not become most discussed stock, due to having failed.

But because it succeeded. Let's state it clear.

8 hedges having spoofed and naked shorting NWBO for +5 years, correlated with Adam Feuerstein having written manipulative lying articles for The Street and STATNEWS for 10 years and dozens of pawns on stockboards doing the dirty bidding of paid bashing ...